Latest Hotspot

FDA Approves Abecma for Hard-to-Treat Multiple Myeloma Post-Two Therapies

9 April 2024
3 min read

Bristol Myers Squibb together with 2seventy bio, Inc. shared the news that the U.S. Food and Drug Administration (FDA) has given the green light for the use of Abecma® (idecabtagene vicleucel; ide-cel) as a therapeutic option for adults suffering from multiple myeloma that has either relapsed or proven resistant following at least two prior therapy attempts, which must have included treatment with an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This approval is rooted in the clinical findings of the KarMMa-3 study.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The authorization of Abecma has been broadened to include its use earlier in the treatment process for individuals who have experienced a relapse or shown resistance following treatment with the three primary classes, post two initial treatment attempts.

"Bryan Campbell, who is the Senior Vice President and the Commercial Head of Cell Therapy at Bristol Myers Squibb, expressed his optimism by stating, ""With a tripled improvement in progression-free survival compared to traditional treatments in cases of relapsed or resistant multiple myeloma, Abecma is set to change the course of therapy for patients much sooner in their treatment timeline.""

Chip Baird, the CEO of 2seventy bio, shared his enthusiasm with the broader accessibility of Abecma for American patients, acknowledging this as a pivotal event for not only the patients and Abecma itself but also for the advances pursued by 2seventy bio in the quest to enhance therapy alternatives and patient outcomes in multiple myeloma.

"The KarMMa-3 trial's findings have been outstanding, particularly when contrasted with the historic results achieved with conventional treatments for these patients dealing with relapsed or resistant diseases," noted Dr. Al-Ola A. Abdallah from the University of Kansas. He holds positions as a Clinical Associate Professor, Clinical Director of Hematologic Malignancies and Cellular Therapeutics, and leads the U.S. Myeloma Innovations Research Collaborative.

Bristol Myers Squibb backs this authorization and its impending extensions by continually investing to boost production capabilities and maintaining an impressively high 94% manufacturing success rate for Abecma in the marketplace.

Notably, Abecma has secured recent approval in Japan, Switzerland, and the European Union for adult patients who have experienced relapse and/or resistance to multiple myeloma after two initial lines of therapy. This positions Abecma distinctly as the singular CAR T cell therapy internationally available for earlier treatment stages in patients harshly affected by triple-class exposed relapsed and/or refractory multiple myeloma. 

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of April 7, 2024, there are 195 investigational drugs for the BCMA target, including 60 indications, 186 R&D institutions involved, with related clinical trials reaching 406, and as many as 14134 patents.

Idecabtagene Vicleucel targets BCMA and has been approved for the treatment of multiple myeloma and relapsed multiple myeloma. The drug has shown potential in various therapeutic areas and has received regulatory designations indicating its importance and urgency. Its first approval in the United States in March 2021 marks a significant milestone in the pharmaceutical industry.

图形用户界面, 文本, 应用程序

描述已自动生成

Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
Hot Spotlight
8 min read
Cell: Designing dual-acting drugs targeting GPCRs using a cheminformatics approach based on variable scaffolds
9 April 2024
On March 28th, the journal "Cell" published an online research paper titled "Flexible Scaffold-based Cheminformatics Approach for Polypharmacological Drug Design".
Read →
Immunome to Showcase Early Research on Its Primary Radiotherapy Agent, IM-3050, at the AACR Meeting in 2024
Latest Hotspot
3 min read
Immunome to Showcase Early Research on Its Primary Radiotherapy Agent, IM-3050, at the AACR Meeting in 2024
9 April 2024
Immunome, Inc. plans to reveal early data on IM-3050, their lead drug featuring lutetium-177, targeting the fibroblast activation protein.
Read →
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
Hot Spotlight
4 min read
The small-molecule CXCR4 antagonist Mavorixafor is used for the treatment of WHIM syndrome and chronic neutropenia
9 April 2024
X4 Pharmaceuticals announced preliminary results from its Phase 2 trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without injected G-CSF in patients with idiopathic, cyclic, or congenital neutropenia.
Read →
Werewolf Therapeutics Unveils Promising Results of WTX-518 and WTX-712 in Cancer Treatment Trial
Latest Hotspot
3 min read
Werewolf Therapeutics Unveils Promising Results of WTX-518 and WTX-712 in Cancer Treatment Trial
9 April 2024
Werewolf Therapeutics Reveals Early Stage Study Outcomes Highlighting the Cancer-Fighting Capabilities of Immune-Stimulating Drugs WTX-518 and WTX-712.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.